Interpretation of the treatment section of Chinese Clinical Practice Guideline on the Management of Ulcerative Colitis (2023, Xi'an)
-
摘要: 近年来，我国溃疡性结肠炎的患病率增长速率较快，提高治疗水平、改善患者预后非常必要。自1993年以来，我国连续制定了多个溃疡性结肠炎治疗方面的共识意见，从治疗目标、原则、药物应用等多方面进行阐述。2023年再次进行了共识意见的修订，并根据牛津分级，对循证证据进行了方法学验证，形成了我国第1版溃疡性结肠炎诊疗指南，本文就指南的治疗部分进行解读，并与2018年共识的治疗部分进行比较，帮助临床医生加深对溃疡性结肠炎治疗基本原则和进展的认识，规范临床行为，并能落实到临床实践工作中。Abstract: In recent years, the incidence of ulcerative colitis(UC) in China has been rapidly increasing, highlighting the necessity of improving treatment strategy to enhance patient prognosis. Since 1993, multiple consensus on the treatment of UC have been continuously formulated in China, elucidating various aspects including treatment goals, principles, and medical applications. In 2023, consensus was revised again, and methodological validation of evidence was conducted using the Oxford grading system, leading to the development of the first edition of UC guidelines in China. This article aims to interpret the treatment section of the UC guidelines and compare it with the consensus on UC treatment from 2018, with the expectation of deepening clinical physicians' understanding of the basic principles and advancements in UC treatment, standardizing clinical behavior, and implementing them in clinical practice.
-
Key words:
- ulcerative colitis /
- treatment /
- guidelines /
- medication management
-
-
[1] He YM, Mao R, Yuan G, et al. The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018[J]. Therap Adv Gastroenterol, 2022, 15: 17562848221102307.
[2] Yang H, Zhou R, Bai X, et al. Trend and Geographic Variation in Incidence and Prevalence of Inflammatory Bowel Disease in Regions Across China: A Nationwide Employee Study Between 2013 and 2016[J]. Front Med(Lausanne), 2022, 9: 900251.
[3] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018年, 北京)[J]. 中华消化杂志, 2018, 38(5): 292-311. doi: 10.3760/cma.j.issn.0254-1432.2018.05.002
[4] 中华医学会消化病学分会炎症性肠病学组, 中国炎症性肠病诊疗质量控制评估中心. 中国溃疡性结肠炎诊治指南(2023年·西安)[J]. 中华消化杂志, 2024, 44(2): 73-79. doi: 10.3760/cma.j.cn311367-20240125-00036
[5] Fukuda T, Naganuma M, Sugimoto S, et al. The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry[J]. PLoS One, 2017, 12(11): e0187737. doi: 10.1371/journal.pone.0187737
[6] Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis[J]. Gastroenterology, 2011, 141(4): 1194-1201. doi: 10.1053/j.gastro.2011.06.054
[7] Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day(800 mg tablet)for the treatment of moderately active ulcerative colitis: the ASCEND Ⅱ trial[J]. Am J Gastroenterol, 2005, 100(11): 2478-2485. doi: 10.1111/j.1572-0241.2005.00248.x
[8] Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis[J]. Am J Gastroenterol, 2011, 106(4): 601-616. doi: 10.1038/ajg.2011.67
[9] Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis[J]. Gastroenterology, 2007, 132(1): 66-75. doi: 10.1053/j.gastro.2006.10.011
[10] Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once-or twice-daily MMX mesalamine(SPD476) for the induction of remission of mild to moderately active ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2007, 5(1): 95-102. doi: 10.1016/j.cgh.2006.10.025
[11] Hartmann F, Stein J, BudMesa-Study Group. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis[J]. Aliment Pharmacol Ther, 2010, 32(3): 368-376. doi: 10.1111/j.1365-2036.2010.04354.x
[12] Feagan BG, Chande N, MacDonald JK. Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews[J]. Inflamm Bowel Dis, 2013, 19(9): 2031-2040.
[13] Shen H, Zhang S, Zhao W, et al. Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis[J]. Biomed Pharmacother, 2021, 139: 111580. doi: 10.1016/j.biopha.2021.111580
[14] Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial[J]. Lancet, 2017, 389(10075): 1218-1228. doi: 10.1016/S0140-6736(17)30182-4
[15] Rossen NG, Fuentes S, van der Spek MJ, et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis[J]. Gastroenterology, 2015, 149(1): 110-118. doi: 10.1053/j.gastro.2015.03.045
[16] Moayyedi P, Surette MG, Kim PT, et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial[J]. Gastroenterology, 2015, 149(1): 102-109. e6. doi: 10.1053/j.gastro.2015.04.001
[17] Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults[J]. Am J Gastroenterol, 2019, 114(3): 384-413. doi: 10.14309/ajg.0000000000000152
-
计量
- 文章访问数: 587
- 施引文献: 0
下载: